This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krystal, G. W. Articles by Litz, J. Search for Related Content PubMed PubMed Citation Articles by Krystal, G. W. Articles by Litz, J.

Induction of Apoptosis and Inhibition of Small Cell Lung Cancer Growth by the Quinoxaline Tyrphostins¹

Departments of Medicine [G. W. K., J. L.], and Microbiology/Immunology [G. W. K., P. C.], Medical College of Virginia/Virginia Commonwealth University and Richmond Veterans Affairs Medical Center, Richmond, Virginia 23249

Coexpression of the Kit receptor tyrosine kinase and its ligand, stem cell factor (SCF), occurs in a high proportion of small cell lung cancers (SCLCs) and drives an autocrine loop that enhances proliferation. To determine whether this autocrine loop affects apoptosis, SCLC cells expressing only SCF or both SCF and Kit were deprived of growth factors for 72 h and the relative number of cells undergoing apoptosis was assessed using nuclear DNA content and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assays. Coexpression of SCF and Kit inhibited apoptosis; apoptosis could, in turn, be enhanced by the addition of the quinoxaline tyrosine kinase inhibitors, which are specific antagonists of the platelet-derived growth factor receptor and Kit. Treatment of the H526 cell line, which is growth-stimulated by soluble SCF, with AG1296 resulted in a marked decrease in growth and an increase in apoptosis in a dose-dependent fashion. Growth inhibition correlated well with the inhibition of Kit tyrosine phosphorylation. The AG1296 compound at its maximum soluble concentration inhibited the growth of 5 of 6 SCLC cell lines in complete medium by an average of 50%. These data suggest that optimized pharmacological inhibitors of Kit activity may be a new class of compounds potentially useful in the treatment of SCLC.

¹ This work was supported by a Merit Review award from the United States Department of Veterans Affairs (to G. W. K.).

² To whom requests for reprints should be addressed, Richmond Veterans Affairs Medical Center (111K), 1201 Broad Rock Boulevard, Richmond, VA 23249. Phone: (804) 675-5446; Fax: (804) 675-5447.

Received 12/ 4/96. Accepted 4/ 4/97.

This article has been cited by other articles:

				R. E. Bolcome III, S. E. Sullivan, R. Zeller, A. P. Barker, R. J. Collier, and J. Chan Anthrax lethal toxin induces cell death-independent permeability in zebrafish vasculature PNAS, February 19, 2008; 105(7): 2439 - 2444. [Abstract] [Full Text] [PDF]

				G. K. Dy, A. A. Miller, S. J. Mandrekar, M.-C. Aubry, R. M. Langdon Jr., R. F. Morton, S. E. Schild, J. R. Jett, and A. A. Adjei A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann. Onc., November 1, 2005; 16(11): 1811 - 1816. [Abstract] [Full Text] [PDF]

				N. C. Wolff, D. E. Randle, M. J. Egorin, J. D. Minna, and R. L. Ilaria Jr. Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3528 - 3534. [Abstract] [Full Text] [PDF]

				J. Litz, P. Carlson, G. S. Warshamana-Greene, S. Grant, and G. W. Krystal Flavopiridol Potently Induces Small Cell Lung Cancer Apoptosis during S Phase in a Manner That Involves Early Mitochondrial Dysfunction Clin. Cancer Res., October 1, 2003; 9(12): 4586 - 4594. [Abstract] [Full Text] [PDF]

				T. J. Abrams, L. B. Lee, L. J. Murray, N. K. Pryer, and J. M. Cherrington SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor {beta} in Preclinical Models of Human Small Cell Lung Cancer Mol. Cancer Ther., May 1, 2003; 2(5): 471 - 478. [Abstract] [Full Text] [PDF]

				T. Kijima, G. Maulik, P. C. Ma, E. V. Tibaldi, R. E. Turner, B. Rollins, M. Sattler, B. E. Johnson, and R. Salgia Regulation of Cellular Proliferation, Cytoskeletal Function, and Signal Transduction through CXCR4 and c-Kit in Small Cell Lung Cancer Cells Cancer Res., November 1, 2002; 62(21): 6304 - 6311. [Abstract] [Full Text] [PDF]

				G. W. Krystal, G. Sulanke, and J. Litz Inhibition of Phosphatidylinositol 3-Kinase-Akt Signaling Blocks Growth, Promotes Apoptosis, and Enhances Sensitivity of Small Cell Lung Cancer Cells to Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 913 - 922. [Abstract] [Full Text] [PDF]

				A. T. Liao, M. B. Chien, N. Shenoy, D. B. Mendel, G. McMahon, J. M. Cherrington, and C. A. London Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors Blood, June 28, 2002; 100(2): 585 - 593. [Abstract] [Full Text] [PDF]

				G. W. Krystal, S. Honsawek, D. Kiewlich, C. Liang, S. Vasile, L. Sun, G. McMahon, and K. E. Lipson Indolinone Tyrosine Kinase Inhibitors Block Kit Activation and Growth of Small Cell Lung Cancer Cells Cancer Res., May 1, 2001; 61(9): 3660 - 3668. [Abstract] [Full Text]

				G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth Clin. Cancer Res., August 1, 2000; 6(8): 3319 - 3326. [Abstract] [Full Text]

				M. C. Heinrich, D. J. Griffith, B. J. Druker, C. L. Wait, K. A. Ott, and A. J. Zigler Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood, August 1, 2000; 96(3): 925 - 932. [Abstract] [Full Text] [PDF]

				C. Bondzi, J. Litz, P. Dent, and G. W. Krystal Src Family Kinase Activity Is Required for Kit-mediated Mitogen-activated Protein (MAP) Kinase Activation, However Loss of Functional Retinoblastoma Protein Makes MAP Kinase Activation Unnecessary for Growth of Small Cell Lung Cancer Cells Cell Growth Differ., June 1, 2000; 11(6): 305 - 314. [Abstract] [Full Text]